Impact of lymph node dissection during surgery on the efficacy of pembrolizumab in patients with metastatic urothelial carcinoma

Keyphrases

• Pembrolizumab 100%
• Metastatic Urothelial Carcinoma 100%
• Lymph Node Dissection 100%
• Overall Survival 62%
• Primary Tumor Resection 25%
• Liver Metastasis 12%
• Multivariate Analysis 12%
• Multivariate Cox Regression Analysis 12%
• Japanese Population 12%
• No Significant Difference 12%
• After Surgery 12%
• Metastasis 12%
• Non-associated 12%
• Urothelial Carcinoma 12%
• Neutrophil-to-lymphocyte Ratio 12%
• Overall Response Rate 12%
• Hemoglobin 12%
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) 12%
• Radical Surgery 12%
• Performance Status 2 12%
• Recurrent Lesions 12%

Medicine and Dentistry

• Transitional Cell Carcinoma 100%
• Pembrolizumab 100%
• Retroperitoneal Lymph Node Dissection 100%
• Overall Survival 62%
• Primary Tumor 25%
• Cancer Surgery 25%
• Proportional Hazards Model 12%
• Liver Metastasis 12%
• Multivariate Analysis 12%
• Cohort Analysis 12%
• Metastatic Carcinoma 12%
• Retrospective Study 12%
• Oncology 12%
• Radical Surgery 12%
• Lymphocyte 12%
• Neutrophil 12%